Salas SJ, Pérez CJI

Idioma: Español
Referencias bibliográficas: 15
Paginas: 12-17
Archivo PDF: 304.61 Kb.

RESUMEN

La cardiotoxicidad asociada al uso de quimioterapéuticos ha sido ampliamente corroborada a través de diversos estudios clínicos. En Costa Rica se han empezado a desarrollar Unidades Cardio-oncológicas en diversos centros médicos con el fin de detectar de manera precoz el efecto deletéreo cardiovascular asociado a los diferentes quimioterapéuticos. A continuación, se presenta un resumen de las manifestaciones clínicas cardiovasculares asociadas al uso de antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS).

REFERENCIAS (EN ESTE ARTÍCULO)

1. Adão R De Keulenaer G Leite-Moreira A Brás-Silva C. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013; 32(5): 395-409.

2. Caja Costarricense de Seguro Social. Lista oficial de medicamentos. 2013. Disponible en www.ccss. sa.cr/lom. Accesado en Marzo del 2018.

3. Lenneman C Sawyer D. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016; 118:1008-1020.

4. Tajiri K Aonuma K Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J clin Oncol. 2017; 47 (8): 678-682.

5. Tan TC Neilan TG Francis S Plana JC Scherrer- Crosbie M. Anthracycline-Induced Cardiomyopathy in Adults. Compr Physiol. 2015; 5 (3): 1517-40.

6. Swain SM Whaley FS Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97-(11): 2869.

7. Ichikawa Y Ghanefar M Bayeva M et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014; 124(2):617-30.

8. Li DL Wang ZV Ding G et al. Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification. Circulation.

9. López-Fernández T Thavendiranathan P. Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Rev Esp Cardiol. 2017, 70(6): 487-495.

10. Cardinale D Sandri MT Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll cardiol. 2000; 36(

11. Cardinale D S):517.andri MT Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high- dose chemotherapy. Circulation. 2004; 109(22): 2749

12. Luminari S Montanini A Caballero D et al. Nonpegylated liposomal doxorubicin (Myoc):20}749.etTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010;21(7):1492.

13. FElker GM Thomsopson RE Hare JM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med.2000;342(15):1077.

14. Wang L Tan TC Halpern EF et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol. 2015; 116(3):442-6.

15. Plana JC Galderisi M Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;27(9):911-39.